Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer

Yu Chen Lee, Song Chang Lin, Guoyu Yu, Chien Jui Cheng, Bin Liu, Hsuan Chen Liu, David H. Hawke, Nila U. Parikh, Andreas Varkaris, Paul Corn, Christopher Logothetis, Robert L. Satcher, Li Yuan Yu-Lee, Gary E. Gallick, Sue Hwa Lin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Resistance to currently available targeted therapies significantly hampers the survival of patients with prostate cancer with bone metastasis. Here we demonstrate an important resistance mechanism initiated from tumor-induced bone. Studies using an osteogenic patient-derived xenograft, MDA-PCa-118b, revealed that tumor cells resistant to cabozantinib, a Met and VEGFR-2 inhibitor, reside in a "resistance niche" adjacent to prostate cancer-induced bone. We performed secretome analysis of the conditioned medium from tumor-induced bone to identify proteins (termed "osteocrines") found within this resistance niche. In accordance with previous reports demonstrating that activation of integrin signaling pathways confers therapeutic resistance, 27 of the 90 osteocrines identified were integrin ligands. We found that following cabozantinib treatment, only tumor cells positioned adjacent to the newly formed woven bone remained viable and expressed high levels of pFAK-Y397 and pTalin-S425, mediators of integrin signaling. Accordingly, treatment of C4-2B4 cells with integrin ligands resulted in increased pFAK-Y397 expression and cell survival, whereas targeting integrins with FAK inhibitors PF-562271 or defactinib inhibited FAK phosphorylation and reduced the survival of PC3-mm2 cells. Moreover, treatment of MDA-PCa-118b tumors with PF-562271 led to decreased tumor growth, irrespective of initial tumor size. Finally, we show that upon treatment cessation, the combination of PF-562271 and cabozantinib delayed tumor recurrence in contrast to cabozantinib treatment alone. Our studies suggest that identifying paracrine de novo resistance mechanisms may significantly contribute to the generation of a broader set of potent therapeutic tools that act combinatorially to inhibit metastatic prostate cancer.

Original languageEnglish
Pages (from-to)4949-4959
Number of pages11
JournalCancer Research
Volume75
Issue number22
DOIs
Publication statusPublished - Nov 15 2015

Fingerprint

Prostatic Neoplasms
Bone and Bones
Integrins
Neoplasms
Bone Neoplasms
Therapeutics
Ligands
Vascular Endothelial Growth Factor Receptor-2
Withholding Treatment
Survival
Conditioned Culture Medium
Heterografts
Cell Survival
Phosphorylation
Neoplasm Metastasis
Recurrence
cabozantinib
Growth
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. / Lee, Yu Chen; Lin, Song Chang; Yu, Guoyu; Cheng, Chien Jui; Liu, Bin; Liu, Hsuan Chen; Hawke, David H.; Parikh, Nila U.; Varkaris, Andreas; Corn, Paul; Logothetis, Christopher; Satcher, Robert L.; Yu-Lee, Li Yuan; Gallick, Gary E.; Lin, Sue Hwa.

In: Cancer Research, Vol. 75, No. 22, 15.11.2015, p. 4949-4959.

Research output: Contribution to journalArticle

Lee, YC, Lin, SC, Yu, G, Cheng, CJ, Liu, B, Liu, HC, Hawke, DH, Parikh, NU, Varkaris, A, Corn, P, Logothetis, C, Satcher, RL, Yu-Lee, LY, Gallick, GE & Lin, SH 2015, 'Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer', Cancer Research, vol. 75, no. 22, pp. 4949-4959. https://doi.org/10.1158/0008-5472.CAN-15-1215
Lee, Yu Chen ; Lin, Song Chang ; Yu, Guoyu ; Cheng, Chien Jui ; Liu, Bin ; Liu, Hsuan Chen ; Hawke, David H. ; Parikh, Nila U. ; Varkaris, Andreas ; Corn, Paul ; Logothetis, Christopher ; Satcher, Robert L. ; Yu-Lee, Li Yuan ; Gallick, Gary E. ; Lin, Sue Hwa. / Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. In: Cancer Research. 2015 ; Vol. 75, No. 22. pp. 4949-4959.
@article{e9c2158c6e274420a5f87ecf98667c90,
title = "Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer",
abstract = "Resistance to currently available targeted therapies significantly hampers the survival of patients with prostate cancer with bone metastasis. Here we demonstrate an important resistance mechanism initiated from tumor-induced bone. Studies using an osteogenic patient-derived xenograft, MDA-PCa-118b, revealed that tumor cells resistant to cabozantinib, a Met and VEGFR-2 inhibitor, reside in a {"}resistance niche{"} adjacent to prostate cancer-induced bone. We performed secretome analysis of the conditioned medium from tumor-induced bone to identify proteins (termed {"}osteocrines{"}) found within this resistance niche. In accordance with previous reports demonstrating that activation of integrin signaling pathways confers therapeutic resistance, 27 of the 90 osteocrines identified were integrin ligands. We found that following cabozantinib treatment, only tumor cells positioned adjacent to the newly formed woven bone remained viable and expressed high levels of pFAK-Y397 and pTalin-S425, mediators of integrin signaling. Accordingly, treatment of C4-2B4 cells with integrin ligands resulted in increased pFAK-Y397 expression and cell survival, whereas targeting integrins with FAK inhibitors PF-562271 or defactinib inhibited FAK phosphorylation and reduced the survival of PC3-mm2 cells. Moreover, treatment of MDA-PCa-118b tumors with PF-562271 led to decreased tumor growth, irrespective of initial tumor size. Finally, we show that upon treatment cessation, the combination of PF-562271 and cabozantinib delayed tumor recurrence in contrast to cabozantinib treatment alone. Our studies suggest that identifying paracrine de novo resistance mechanisms may significantly contribute to the generation of a broader set of potent therapeutic tools that act combinatorially to inhibit metastatic prostate cancer.",
author = "Lee, {Yu Chen} and Lin, {Song Chang} and Guoyu Yu and Cheng, {Chien Jui} and Bin Liu and Liu, {Hsuan Chen} and Hawke, {David H.} and Parikh, {Nila U.} and Andreas Varkaris and Paul Corn and Christopher Logothetis and Satcher, {Robert L.} and Yu-Lee, {Li Yuan} and Gallick, {Gary E.} and Lin, {Sue Hwa}",
year = "2015",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-15-1215",
language = "English",
volume = "75",
pages = "4949--4959",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer

AU - Lee, Yu Chen

AU - Lin, Song Chang

AU - Yu, Guoyu

AU - Cheng, Chien Jui

AU - Liu, Bin

AU - Liu, Hsuan Chen

AU - Hawke, David H.

AU - Parikh, Nila U.

AU - Varkaris, Andreas

AU - Corn, Paul

AU - Logothetis, Christopher

AU - Satcher, Robert L.

AU - Yu-Lee, Li Yuan

AU - Gallick, Gary E.

AU - Lin, Sue Hwa

PY - 2015/11/15

Y1 - 2015/11/15

N2 - Resistance to currently available targeted therapies significantly hampers the survival of patients with prostate cancer with bone metastasis. Here we demonstrate an important resistance mechanism initiated from tumor-induced bone. Studies using an osteogenic patient-derived xenograft, MDA-PCa-118b, revealed that tumor cells resistant to cabozantinib, a Met and VEGFR-2 inhibitor, reside in a "resistance niche" adjacent to prostate cancer-induced bone. We performed secretome analysis of the conditioned medium from tumor-induced bone to identify proteins (termed "osteocrines") found within this resistance niche. In accordance with previous reports demonstrating that activation of integrin signaling pathways confers therapeutic resistance, 27 of the 90 osteocrines identified were integrin ligands. We found that following cabozantinib treatment, only tumor cells positioned adjacent to the newly formed woven bone remained viable and expressed high levels of pFAK-Y397 and pTalin-S425, mediators of integrin signaling. Accordingly, treatment of C4-2B4 cells with integrin ligands resulted in increased pFAK-Y397 expression and cell survival, whereas targeting integrins with FAK inhibitors PF-562271 or defactinib inhibited FAK phosphorylation and reduced the survival of PC3-mm2 cells. Moreover, treatment of MDA-PCa-118b tumors with PF-562271 led to decreased tumor growth, irrespective of initial tumor size. Finally, we show that upon treatment cessation, the combination of PF-562271 and cabozantinib delayed tumor recurrence in contrast to cabozantinib treatment alone. Our studies suggest that identifying paracrine de novo resistance mechanisms may significantly contribute to the generation of a broader set of potent therapeutic tools that act combinatorially to inhibit metastatic prostate cancer.

AB - Resistance to currently available targeted therapies significantly hampers the survival of patients with prostate cancer with bone metastasis. Here we demonstrate an important resistance mechanism initiated from tumor-induced bone. Studies using an osteogenic patient-derived xenograft, MDA-PCa-118b, revealed that tumor cells resistant to cabozantinib, a Met and VEGFR-2 inhibitor, reside in a "resistance niche" adjacent to prostate cancer-induced bone. We performed secretome analysis of the conditioned medium from tumor-induced bone to identify proteins (termed "osteocrines") found within this resistance niche. In accordance with previous reports demonstrating that activation of integrin signaling pathways confers therapeutic resistance, 27 of the 90 osteocrines identified were integrin ligands. We found that following cabozantinib treatment, only tumor cells positioned adjacent to the newly formed woven bone remained viable and expressed high levels of pFAK-Y397 and pTalin-S425, mediators of integrin signaling. Accordingly, treatment of C4-2B4 cells with integrin ligands resulted in increased pFAK-Y397 expression and cell survival, whereas targeting integrins with FAK inhibitors PF-562271 or defactinib inhibited FAK phosphorylation and reduced the survival of PC3-mm2 cells. Moreover, treatment of MDA-PCa-118b tumors with PF-562271 led to decreased tumor growth, irrespective of initial tumor size. Finally, we show that upon treatment cessation, the combination of PF-562271 and cabozantinib delayed tumor recurrence in contrast to cabozantinib treatment alone. Our studies suggest that identifying paracrine de novo resistance mechanisms may significantly contribute to the generation of a broader set of potent therapeutic tools that act combinatorially to inhibit metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84955267503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955267503&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-1215

DO - 10.1158/0008-5472.CAN-15-1215

M3 - Article

C2 - 26530902

AN - SCOPUS:84955267503

VL - 75

SP - 4949

EP - 4959

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 22

ER -